StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Sanofi, Alnylam Pharmaceuticals (ALNY) Announces APOLLO Phase 3 Study of Patisiran Met Primary Efficacy Endpoint and All Secondary Endpoints
September 20, 2017 7:02 AM
Sanofi Genzyme and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that the APOLLO Phase 3 study of patisiran, an investigational ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Hot Corp. News
Hot FDA News
Trading Halts
Next Articles
UPDATE: Alnylam Pharmaceuticals (ALNY) PT Raised to $146 at Ladenburg Thalmann
September 21, 2017 7:04 AM
Alnylam Pharmaceuticals (ALNY) PT Raised to $123 at Credit Suisse
September 21, 2017 6:26 AM
Alnylam Pharmaceuticals (ALNY) PT Raised to $125 at Needham & Company
September 20, 2017 3:20 PM
Alnylam Pharmaceuticals (ALNY) PT Raised to $128 at JMP Securities
September 20, 2017 2:14 PM
Alnylam Pharmaceuticals (ALNY) PT Raised to $83 at Stifel
September 20, 2017 1:41 PM
Alnylam Pharmaceuticals (ALNY) PT Raised to $117 at Cowen; 'Best-Case Scenario'
September 20, 2017 12:36 PM
Alnylam Pharmaceuticals (ALNY) PT Raised to $116 at Piper Jaffray
September 20, 2017 11:39 AM
Alnylam Pharma (ALNY) Adds to Gains; Shares up 40%
September 20, 2017 10:23 AM
Alnylam Pharma (ALNY) Gains 22% on Patisiran Phase 3 Trial Success
September 20, 2017 7:53 AM
Alnylam Pharma (ALNY) to Resume Trading at 7:30 AM ET
September 20, 2017 7:06 AM
Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
September 20, 2017 7:00 AM
